Revisiting signatures of neutral tumor evolution in the light of complexity of cancer genomic data To the Editor -Tumors arise as a result of evolutionary processes operating on somatic cells within tissues, and thus identifying the modes of cancer evolution is of fundamental interest. In an analysis of whole-exome-and whole-genomesequencing data for 904 samples from 14 different cancer types and cohorts, Williams et al. 1 have reported that the mutant-allele frequencies of approximately one-third (323/904) of the samples follow a simple power-law distribution (mean R 2 ~0.90-0.98 for each cohort) and have inferred that subclones in those tumors are under neutral evolution. In that study, the authors used mutant-allele frequency from whole-genome-and whole-exomesequencing data as a direct proxy for the relative fraction of tumor cells carrying that mutation, and they fitted the power law directly to the distributions of mutant-allele-frequency estimates. This procedure can introduce different types of biases. Various steps of the genomic pipeline including tumor-DNA extraction, PCR amplification, and sequencing protocols introduce variability 2 , such that allelic proportional read counts do not automatically indicate clonal proportion and instead follow a distribution with the underlying clonal proportion as a prior in diploid regions. Additional variation in allele-frequency estimates could arise because of copy number alterations and pathological tumor purity. Williams et al. 1 selected only high-purity tumors (≥ 70%), and analyzed regions with copy number absolute log R ratio ≤ 0.5, but these filters were lenient, and purity and ploidy estimates were not explicitly included in the model. As we show below, these attributes can collectively contribute to a moderate level of overdispersion of the allele-frequency distribution of somatic mutations and present challenges in fitting the power-law distribution.
Analyzing copy number and exomesequencing data for > 300 paired tumornormal samples from The Cancer Genome Atlas (TCGA) 3 bladder, lung, and colon cancers, and focusing on the genomic regions with absolute log R ratio ≤ 0.5 (details in Supplementary Methods), we observed that most of the samples had greater dispersion in the read-count-based allelic-frequency distribution of germline SNPs in the tumor genomes than in the matched normal genomes. This result is partly due to low-allele-frequency somatic subclonal copy number events (for example, absolute log R ratio ≤ 0.5) in the tumor genomes (Fig. 1a,b) . We then examined the effects of the dispersion of the somatic allele-frequency distribution in tumor genomes on the power-law fit. Following an established approach 4 , we fitted a beta-binomial model to the allele-frequency distributions of germline variants to the TCGA samples to account for overdispersion and estimated model parameters, and we then applied similar dispersion parameters to realistically model read-count-based allelic frequencies for somatic variants in tumor genomes with one, two, or a few subclones. Using representative examples, we demonstrate that the power-law distribution shows an excellent fit to the allele-frequency distributions (R 2 0.90-0.99) within the allele-frequency range of 0.12-0.25 used by Williams et al. 1 , even when the allele-frequency data were derived from simulated tumor genomes with one to three subclones and 80× median coverage (Fig. 1c,d ). Our results were not sensitive to model selection. For instance, we also obtained a good fit to the power law when overdispersion was ignored, and binomial distribution was used to simulate allele-frequency distributions in tumor genomes with two or three subclones and 80× median coverage (Fig. 1e,f) . Synthetic genomes may not capture different levels of complexity of biological data from real human tumors. Therefore, we further obtained data on the estimates of the number of clones in the same tumor from a published study 5 , which took into account point mutations, purity estimates, and copy number alterations to estimate clonality. Among the TCGA tumor samples identified by Williams et al. 1 to have strong signatures of neutral evolution (R 2 all > 0.99), 27/79 (35%) and 21/79 (26%) were reported to have two to four clones (oligoclonal) and eight or more clones (polyclonal), respectively. These observations suggest that a significant fit to the power law within the allele-frequency range 0.12-0.25 could be achieved under multiple alternate hypotheses, and the null hypothesis may not be reliably rejected. Thus, caution should be taken when inferring neutral evolution, in light of the complexity of genomic data. It is plausible that each subclone may comprise populations of tumor cells with genetic heterogeneity among themselves, but the TCGA data did not have sufficient depth of coverage and resolution to address that possibility.
Second, the depth of coverage for whole-exome-and whole-genomesequencing data of most of the cohorts chosen, including the TCGA 3 , allows for detection of only somatic mutations with allele frequency > 10% (or > 5% in some cases). At this allele-frequency resolution, it is possible to detect only the principal clonal branches, but the depth of sequencing coverage in these data is not suitable for detecting the 'twigs' and 'leaves' . For instance, at an allele-frequency threshold of 0.1, it is possible to detect only heterozygous mutations in clones that constitute > 20% of the tissue mass, even if issues due to tumor purity and variations in read counts are adjusted for. Consequently, beyond the major branches, these data provide no information about the fractal topology of the twigs and leaves in the evolutionary tree in Fig. 5 of Williams et al. 1 , and no inference about M(f) versus 1/f (where M is the cumulative frequency distribution, and f is allele frequency) could be made for those subregions of the tree.
Nonetheless, Williams et al. 1 have provided a valuable conceptual framework to integrate tumor genomic data with theoretical population dynamics to identify and compare modes of tumor evolution, which would stimulate further advances in this area and may have future implications for clinical management of patients with cancer. 
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Code is available in Supplementary Methods. question the applicability of the power-law neutral-evolution model to adequately describe the pattern of subclonal somatic mutations in bulk cancer sequencing data. The authors' letter focuses on the issues of the inherent noise in next-generation sequencing data, whereby random sampling of alleles, PCR amplification during library preparation, limited depth sequencing, and subclonal copy number changes may cause considerable uncertainty in variantallele frequency (VAF) measurement. The authors suggest that these errors lead to VAF measurements that, owing to overdispersion, follow a beta-binomial and not a binomial distribution. We thank Balaparya and De for the insightful comments and address their points in the response below.
Data availability
The issue of VAF measurement accuracy is a very important point and something that concerned us in our original study 2 . For this reason, we provided extensive error-propagation analysis in our original manuscript to identify the inherent biases that affect VAF estimation (Methods and equations (12)- (14) in ref.
2 ). We aimed at starting from the analytical form of neutral evolution (equation (7) in ref.
2 ) as the expected signal (S) and adding the different sources of noise (N), such as purity and allele sampling during library preparation, to generate the expected pattern S + N reported by the data. Our results demonstrate that the signature of neutral evolution is detectable with moderately high sequencing depth (≥ 100× ; Methods and Supplementary Fig. 10 in ref. 2 ), and we fully acknowledged that the signature of neutral evolution versus selection cannot be reasonably extracted (or rejected) from lower-depth datasets.
In an effort to address Balaparya and De's concerns, we tested the ability of our model to recover neutral evolutionary dynamics in the presence of beta-binomially distributed noise, and we found no significant differences with respect to the binomial noise used in our original manuscript, although with very high dispersion (ρ = 0.1), a degree of difference was appreciable (Fig. 1a) . Moreover, we estimated the degree of overdispersion in the data that we analyzed in ref.
2 by fitting a beta-binomial model to the clonal cluster by using Markovchain Monte Carlo inference. In both the 100× whole-genome gastric cancer 3 and whole-exome colon cancer 4 data, we estimated the dispersion parameter ρ to be < 0.005 (Fig. 1b,c, respectively) , a value notably 10× lower than postulated by Balaparya and De (Fig. 1c,d in ref.   1 ). Given that as ρ→ 0, the beta-binomial distribution converges to a binomial distribution, we argue that using a binomial distribution to model noise in sequencing data was appropriate in our original analysis.
Balaparya and De also suggest that, because copy number alterations affect VAF distributions, very strict thresholds are necessary to ensure that regions analyzed with our method are truly diploid. This is an important point, and we concur that the original threshold of absolute log R ratio ≤ 0.5 may have been too lenient. To test the effect of this confounding factor, we reanalyzed the TCGA pan-cancer dataset by using the new publicly accessible Genomic Data Commons Data Portal (see URLs) variant calls, which were not available at the time of our original manuscript. We downloaded data from 8,455 TCGA tumors of different cancer types and selected cancers with high purity (≥ 70%) by using variants called with Mutect2, as we did in our original manuscript. We then adjusted the VAF for the purity obtained from ref. 5 and identified diploid regions by using absolute copy number calls from ref. 6 . We then classified tumors as neutral/ non-neutral, by using mutations in regions with copy number n = 2. We used the allele frequency f = [0.12, 0.24] integration range and required a minimum of 12 subclonal mutations, as in our original manuscript. Out of the 8,455 tumors, 724 satisfied all the conditions (reasons for exclusion in Supplementary Fig. 1 ). This analysis confirmed our original findings with a similarly large proportion of tumors classified as neutral: 40% of neutral cases were identified in this cohort (290/724), compared with 31% in our original analysis (Supplementary Table 1 ). Hence, these confounding factors are more likely to lead to incorrect rejection of the neutral model rather than incorrect acceptance. In terms of copy number alterations, this conclusion makes sense, because they would generate binomial clusters in the VAF distribution that would erroneously appear as subclonal clusters.
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Data collection
As described in the Supplementary methods, we downloaded already processed variant calls based on exome sequencing data (Mutect pipeline) and copy number segmentation calls (Affymetrix SNP-6 array) for the TCGA Cancer Genome Atlas (TCGA) bladder, breast, lung, and colon cancer samples from the National Cancer Institute GDC Data portal Legacy Archive (https://portal.gdc.cancer.gov/legacyarchive).
Data analysis
We have provided the complete R code of the analysis as Supplementary Methods.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
